Bailard’s CorMedix CRMD Stock Holding History

Bailard’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-15,500	Closed	-$122K	–	765
2026 Q2	$122K	Buy	+15,500	New	+$122K	﹤0.01%	754
2026 Q1	–	Sell	-12,200	Closed	-$142K	–	759
2025 Q4	$142K	Buy	+12,200	New	+$135K	﹤0.01%	728

Other funds holding CRMD

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Bailard's CRMD Position: Q3 2026 in Review

Bailard sold out of CorMedix (CRMD) in Q3 2026, closing a stake of 15,500 shares — an estimated $122K sold.

Bailard first reported a position in CRMD in Q4 2025 and held it in 2 quarters. The position peaked at $142K in Q4 2025. 6 funds tracked by Wall St. Rank hold CRMD as of Q3 2026.

Bailard reported no remaining CorMedix position as of Q3 2026 after selling out during the quarter.
Bailard sold 15,500 CorMedix shares in Q3 2026, an estimated $122K.
Bailard first reported a position in CorMedix in Q4 2025 and held it in 2 quarters.
Bailard's CorMedix position peaked at $142K in Q4 2025.
6 funds tracked by Wall St. Rank held CorMedix as of Q3 2026.

Based on Bailard's 13F filing for Q3 2026, filed 13 Oct 2026.